Candel Therapeutics (CADL) Projected to Announce Earnings on Thursday

Candel Therapeutics (NASDAQ:CADL) will likely be issuing its Q3 2026 results before the market opens on Thursday, November 12th. Analysts expect Candel Therapeutics to announce earnings of ($0.3372) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Friday, November 13, 2026 at 9:30 AM ET.

Candel Therapeutics (NASDAQ:CADL) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.28). On average, analysts expect Candel Therapeutics to post ($1.29) EPS for the current fiscal year and ($1.27) EPS for the next fiscal year.

Candel Therapeutics Stock Performance

Shares of CADL stock opened at $9.05 on Thursday. The company has a current ratio of 16.09, a quick ratio of 16.09 and a debt-to-equity ratio of 0.38. The firm has a fifty day simple moving average of $10.41 and a two-hundred day simple moving average of $8.31. Candel Therapeutics has a 12 month low of $4.35 and a 12 month high of $14.00. The firm has a market capitalization of $692.51 million, a PE ratio of -6.42 and a beta of -0.27.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on CADL shares. Wall Street Zen cut shares of Candel Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, August 16th. Stifel Nicolaus started coverage on shares of Candel Therapeutics in a report on Monday, July 13th. They issued a “buy” rating and a $22.00 target price on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Candel Therapeutics in a report on Thursday, October 15th. Bank of America raised shares of Candel Therapeutics from a “neutral” rating to a “buy” rating and raised their price target for the company from $12.00 to $18.00 in a research report on Monday, September 21st. Finally, Zacks Research downgraded Candel Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Wednesday, October 14th. Nine analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $21.43.

Insider Activity

In other Candel Therapeutics news, CTO Seshu Tyagarajan sold 7,000 shares of the company’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $12.00, for a total value of $84,000.00. Following the completion of the sale, the chief technology officer directly owned 76,865 shares of the company’s stock, valued at approximately $922,380. This represents a 8.35% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 14.30% of the stock is currently owned by insiders.

About Candel Therapeutics

Candel Therapeutics, Inc is a clinical-stage biopharmaceutical company developing biological immunotherapies designed to stimulate the immune system to recognize and attack cancer. The company’s approach uses engineered viral therapies intended to promote immunogenic cell death and generate broader, potentially systemic antitumor immune responses.

Candel’s pipeline includes CAN-3110, an investigational oncolytic immunotherapy based on a genetically engineered herpes simplex virus type 1.